Table 5
Prevalence of decreased white blood cells (WBCs), and abnormal liver function (SGOT, SGPT, and RGT) by sex
| Sex/department | White blood cells | SGOT | SGPT | RGT |
|---|---|---|---|---|
| *p<0.05; **p<0.1; †OR=crude odds ratio; AOR=odds ratio adjusted by age, cigarette smoking, alcohol drinking, hepatitis B surface antigen, and body mass index. | ||||
| Men: | ||||
| Photolithography (n=20) (n (%)) | 6 (30) | 1 (5) | 3 (15) | 2 (10) |
| OR (95% CI)† | 7.3** (0.96 to 55.6) | 0.4 (0.01 to 6.9) | 0.9 (0.12 to 6.7) | 0.4 (0.04 to 3.1) |
| AOR (95% CI)‡ | 8.1** (0.83 to 78.3) | 0.4 (0.02 to 5.8) | 0.8 (0.11 to 5.1) | 0.4 (0.05 to 3.74) |
| Implantation (n=19) (n (%)) | 4 (21.1) | 0 (0) | 2 (10.5) | 1 (5.3) |
| OR (95% CI) | 4.5 (0.5 to 45.2) | 0.6 (0.06 to 5.3) | 0.2 (0.01 to 2.3) | |
| AOR (95% CI) | 3.7 (0.36 to 39.3) | 0.9 (0.11 to 7.1) | 0.4 (0.03 to 5.7) | |
| Etching and diffusion (n=57) (n (%)) | 8 (14) | 4 (7.0) | 12 (21.1) | 5 (8.8) |
| OR (95% CI) | 2.8 (0.32 to 23.9) | 0.6 (0.08 to 5.3) | 1.3 (0.3 to 6.9) | 0.3 (0.07 to 1.8) |
| AOR (95% CI) | 3.3 (0.37 to 28.8) | 0.6 (0.08 to 13.1) | 1.2 (0.3 to 5.3) | 0.3 (0.05 to 1.65) |
| Office (n=18) (n (%)) | 1 (5.6) | 2 (11.1) | 3 (16.7) | 4 (22.2) |
| OR (95% CI) | 1.0 | 1.0 | 1.0 | 1.0 |
| AOR (95% CI) | 1.0 | 1.0 | 1.0 | 1.0 |
| Women: | ||||
| Photolithography (n=34) (n (%)) | 4 (11.8) | 2 (5.9) | 6 (17.7) | 2 (5.9) |
| OR (95% CI) | 0.8 (0.2 to 3.7) | 1.8 (0.1 to 51.7) | 6.0** (0.63 to 141) | 4.5 (0.21 to 98.5) |
| AOR (95% CI) | 0.5 (0.1 to 2.44) | 2.4 (0.16 to 34) | 9.6** (0.86 to 107) | 6.4** (0.53 to 75.8) |
| Etching and diffusion (n=50) (n (%)) | 6 (12) | 4 (8) | 4 (8) | 2 (4) |
| OR (95% CI) | 0.9 (0.22 to 3.3) | 2.4 (0.23 to 60.2) | 2.4 (0.23 to 60.2) | 3.0 (0.14 to 65.6) |
| AOR (95% CI) | 0.6 (0.15 to 2.5) | 4.2 (0.36 to 48.4) | 4.6 (0.4 to 51.9) | 3.3 (0.26 to 43.1) |
| Office (n=29) (n (%)) | 4 (13.8) | 1 (3.5) | 1 (3.5) | 0 (0) |
| OR (95% CI) | 1.0 | 1.0 | 1.0 | 1.0 |
| AOR (95% CI) | 1.0 | 1.0 | 1.0 | 1.0 |
